Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women
D. Carati1,*, A. Zizza2, M. Guido3, A. De Donno3, R. Stefanizzi1, R. Serra4, I. Romano4, C. Ouedraogo5, M. Megha6, A. Tinelli7
1 Research & Development Department, Ekuberg Pharma srl, Martano
2 Institute of Clinical Physiology, National Research Council, Lecce
3 Laboratory of Hygiene, Department of Biological and Environmental Sciences and Technologies, Faculty of Sciences, University of Salento, Lecce
4 Department of Diabetology, Poliambulatory “Cittadella della Salute”, Lecce (Italy)
5 Department of Obstetrics and Gynecology, Teaching Hospital of Ouagadougou, Ouagadougou (Burkina Faso)
6 Laboratory of Clinical Pathology, Poliambulatory “Cittadella della Salute” Lecce
7 Department of Obstetrics and Gynecology, Division of Experimental Endoscopic Surgery, Imaging, Technology and Minimally Invasive Therapy, Vito Fazzi Hospital, Lecce (Italy)
Clin. Exp. Obstet. Gynecol. 2016, 43(2), 198–202; https://doi.org/10.12891/ceog3078.2016
Published: 10 April 2016
Background: Problems affecting the vaginal tract in diabetic women are very often neglected. The efficacy and safety of three gynecological treatments in diabetic women have been assessed. Materials and Methods: A single-blind randomized progressive trial on 48 diabetic women affected by vaginal dryness, dyspareunia, and recurrent Candida infections was carried out. The ICIQ Vaginal Symptoms (ICIQ-VS) questionnaire was administered. Results: The analysis of the parameters of ICIQ-VS questionnaire among the three groups showed significant difference only for “dragging pain” (p = 0.019) and “soreness” (p = 0.028). In all groups and for all parameters of the questionnaire, improvement of symptoms was observed. In particular, in Group 1 for all symptoms a highly significant difference was observed, to support the already known benefits of the products and of the proposed combination. Significant improvement was also observed in Group 2. Conclusions: The proposed treatment with DermoXENR Ultracalming Special for diabetics and DermoXEN R Vitexyl vaginal gel exert effective moisturizing and soothing action. Indeed, the aforementioned products have been proven effective for the main gynecological problems of diabetic women.